Moberg Pharma is excited to announce the appointment of Dr. Cindy Wong as its new Chief Medical Officer. In this position, Dr. Wong will be responsible for accelerating the development and commercialization of novel treatments for the medical company this coming fall.
"We look forward to welcoming Cindy to Moberg Pharma. She will be joining the company in a highly exciting stage as we recently completed phase 3-trials for MOB-015, where she will be adding valuable experience from the development, registration, and commercialization of novel treatments", says Anna Ljung, CEO Moberg Pharma.
D. Wong has a strong background in the field of medicinal research, previously standing as Vice President and Head of Global Clinical Development at Metz Pharmaceuticals GmbH and Chief Medical Officer at Q-Med/Galderma. She is a medical graduate of the University of Adelaide and completed her postgraduate training in Internal Medicine, Clinical Immunology, and Immunopathy, in which she is now board certified.